EE227 Healthcare Resource Utilization and Costs Among Patients with Moderately-to-Severely Active Crohn’s Disease Treated with Ustekinumab: Real-World Evidence
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.475
https://www.valueinhealthjournal.com/article/S1098-3015(22)02679-1/fulltext
Section Title :
Section Order :
12282
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02679-1&doi=10.1016/j.jval.2022.09.475